$40 Million

Otonomy

At-the-market Offering

Otonomy
Otonomy a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear in the United States and Canada. Its lead product candidate is AuriPro, a sustained-exposure antibiotic, which completed Phase III clinical trials to treat pediatric patients with middle ear effusion or fluid at the time of tympanostomy tube placement surgery. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone that is in a Phase IIb clinical trial for the treatment of patients with Ménière’s disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in preclinical development as a potential treatment for tinnitus.